Please wait while we load the requested 10-Q report or click the link below:
miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
|◾||MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA)|
|◾||miRagens collaboration with Servier extended with the objective to start testing MRG-110 in humans within a year|
|◾||MRG-106 clinical data to be presented at ASCO in June 2017|
|◾||Cash balance sufficient to fund operations through 2018|
|◾||Conference call today at 4:30 p.m. ET|
BOULDER, CO, May 10, 2017 (GLOBE NEWSWIRE) Miragen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced first quarter 2017 financial results and provided a corporate update.
It has been an exciting and productive first quarter of 2017, with encouraging business developments and clinical progress to report, said William S. Marshall, Ph.D., president and chief executive officer of miRagen Therapeutics. We continue to be encouraged by the interim results from our MRG-106 and MRG-201 Phase 1 clinical trials, and plan to provide updated clinical data at scientific conferences throughout the year. We also completed a merger to become a public company and concurrent financing during the quarter. With a cash runway through 2018, we believe we are well-positioned to deliver clinical data from our existing trials, expand these trials, and provide additional data that may broaden the potential clinical applications of our lead programs.
Business Highlights and Update
|◾||Completed merger to become a public company: On February 13, 2017, miRagen completed a merger with Signal Genetics, Inc., and the Company began trading on the NASDAQ Capital Market under the ticker symbol MGEN on February 14, 2017.|
|◾||Raised $40.7 million though an equity financing: Concurrent with the merger, the Company also completed a private placement of its common stock with gross proceeds of approximately $40.7 million immediately prior to the merger.|
The following information was filed by Miragen Therapeutics, Inc. (MGEN) on Wednesday, May 10, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Miragen Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Miragen Therapeutics, Inc..